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A prospective study of renal structure and function in psoriasis
patients treated with cyclosporin. The impact of tong-term cyclosporin
therapy on kidney structure and function was evaluated in psoriasis
patients with normal baseline renal function. Patients received cyclosporin
at an average dose 3.9 mg/kg/day for up to three years and underwent
serial kidney biopsies and measurements of iothalamate clearance and
serum creatinine concentration. Kidney biopsy specimens (assessed on a
scale of 0 to 4 where 0 = normal and 4 = severe) from 19 cyclosporin-
treated patients as compared to 38 age-matched transplant donors showed
increased interstitial fibrosis (1.9 0.2 vs. 0.3 0.1, P < 0.0001) and
tubular atrophy (1.6 0.2 vs. 0.3 0.1, P C 0.0001) at one year. Eleven
patients had a second biopsy after an additional two years of cyclosporin
treatment demonstrating additional interstitial fibrosis (1.8 0.2 to 2.4
0.3, P = 0.002) and tubular atrophy (1.4 0.2 to 1.9 0.2, P = 0.053), and
the onset of cyclosporin-associated arteriolopathy (0 to 0.5 0.2, P =
0.02). Ouantitative digital morphometric analysis of trichrome-stained
specimens also showed increased interstitial fibrosis (22.5 1.5 to 32.0
2.0% of interstitial area,P = 0.0008). lothalamate clearance declined at an
average rate of —3.1 ml/min/1.73 m2 per year (95% CI —5.8, —0.3) during
the period of cyclosporin treatment. The slope of reciprocal serum
creatinine declined by —0.06 dl/mg per year (95% CI —0.08, —0.04).
Chronic cyclosporin treatment of otherwise healthy psoriasis patients is
associated with progressive renal structural injury and reduced glomerular
filtration rate.
Cyclosporin is the mainstay of immunosuppressive therapy in
organ transplantation and is being used increasingly for the
treatment of various inflammatory and autoimmune diseases,
including psoriasis [1], However, the benefits of cyclosporin for
non-transplant indications must be balanced against the long-term
risks, particularly nephrotoxicity. Renal toxicity, which is well
described in transplant patients, may not occur to the same degree
in other patient groups because of differences in baseline renal
function, concomitant diseases and medications, cyclosporin dose,
and the confounding effect of rejection. To make judgments about
the risk of cyclosporin therapy in non-transplant patients, it is
important to understand the long-term renal side effects of
cyclosporin when given alone in low doses over an extended
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period of time to patients with normal baseline renal function and
few other confounding factors.
To address this issue, we performed serial assessments of renal
structure and function in a selected group of psoriasis patients
treated with cyclosporin for up to three years. Because psoriasis is
not associated with kidney abnormalities, we were able to assess
the direct renal effect of cyclosporin in the absence of substantive
interference by concurrent diseases or therapy.
Methods
Study design and subjects
This report describes a group of patients who received oral
cyclosporin (Sandimmune®, Sandoz Pharmaceuticals Corp.) for
up to three years in whom renal structure and function were
systematically assessed. The study group was drawn from a larger
group of patients with severe or disabling chronic psoriasis who
were previously enrolled in a prospective study of the efficacy and
safety of oral cyclosporin for the treatment of psoriasis [2]. At
entry to the original study, patients had a normal serum creati-
nine, blood pressure 150/90 mm Hg, and no history of kidney
disease. Patients were initially treated with cyclosporin at doses of
3.5 to 7.5 mg/kg per day for two months. Patients who had
complete or near-complete clearing of their psoriasis were then
treated with doses of 1.5 to 5 mg/kg per day (as necessary to
maintain remission) for another 10 months. At the end of
approximately one year of therapy, cyclosporin was stopped.
At this one-year point, twenty-five patients agreed to partici-
pate in the current study of the long-term renal effects of
cyclosporin. Twenty patients successfully underwent a kidney
biopsy; five patients did not have a biopsy due to technical or
logistical problems. The kidney biopsy from one patient showed
dense focal inflammatory infiltrates in scarred areas suggesting
chronic interstitial nephritis or chronic pyelonephritis unrelated
to cyclosporin use; this patient was withdrawn from the study and
excluded from analysis.
All remaining patients had recurrence of psoriasis after a one to
two month medication-free period and resumed cyclosporin at
dosages of up to 5 mg/kg per day. The dose was decreased to the
lowest effective level or in response to a decline in renal function,
indicated by changes in the serum creatinine concentration or
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iothalamate clearance rate. Subsequently, one patient had a
cerebrovascular accident and was withdrawn. Three patients died
(accident, suicide, and colon cancer). Five patients withdrew
because they or their physician were concerned about possible
cyclosporin nephrotoxicity. In all, 16 patients were treated with
cyclosporin for an additional two years (3 years total) including 11
patients who had an initial biopsy and the five patients who did
not. Fourteen patients underwent a kidney biopsy after approxi-
mately three years of therapy including all 11 patients who had an
initial biopsy and were still enrolled in the study.
Throughout the study, patients were instructed to avoid aspirin
or other non-steroidal anti-inflammatory drugs, potentially neph-
rotoxic drugs and drugs known to alter cyclosporin metabolism
(for example, ketoconazole, erythromycin, phenytoin, barbitu-
rates, carbamazepine, isoniazid, or rifampin). All patients were
informed of the details, procedures, and potential risks of the
study and gave written consent for all treatments and procedures.
The protocol was approved by the Institutional Review Board of
the University of Michigan Medical Center and an application for
the use of an investigational new drug was filed by the manufac-
turer with the Food and Drug Administration.
Kidney biopsies
Percutaneous kidney biopsies were performed with ultrasound
localization using standard techniques. Tissue was fixed in forma-
lin and stained with hematoxylin and eosin, PAS, and trichrome
and evaluated by light microscopy. The biopsy specimens were
read and scored by two pathologists (KJJ, MJM) who were
blinded to the clinical data and the temporal sequence of the
biopsies. The pathologists jointly scored the specimens using an
ordinal scale designed for evaluation of cyclosporin nephrotoxicity
[3, 4]. The degree of interstitial fibrosis, tubular atrophy, arteriolar
hyalinosis, and cyclosporin-associated arteriolopathy was each
scored on a scale of 0 to 4 (0 = absence of abnormality, 1 =
minimal changes in a few sections, 2 = slight changes present in
all sections, 3 = medium severe changes, and 4 = severe changes).
Arteriolar hyalinosis is not considered to be specific for cyclospo-
rin. Cyclosporin-associated arteriolopathy is characterized by
transmural nodular deposits in the arteriolar wall and mucoid
intimal thickening [3, 4]. The percent of glomeruli displaying
obsolescence and juxtaglomerular hypertrophy was measured.
Specimens from the patients who underwent two kidney biop-
sies were also evaluated with the semiquantitative lupus chronicity
index [5] and by a quantitative digital morphometric technique.
The lupus chronicity index is the sum of individual scores for
interstitial fibrosis, tubular atrophy, glomerular sclerosis, and
fibrous crescents, each rated on a scale of 0 to 3 (0 absent, 1 =
mild, 2 = moderate, 3 = severe) [5]. For the quantitative
morphometric analysis, the interstitial areas of trichrome-stained
biopsy slides were scanned with a video imaging system (Olympus
BH-2 microscope connected to a Sony CCD/RGB color video
camera) at 40X magnification using IP Lab Spectrum software
(Signal Analytic Corp., Vienna, Virginia, USA) and a Macintosh
IIfx computer. Scanning windows were set for each specimen to
quantify blue staining representing interstitial fibrosis. All avail-
able fields were scanned for each biopsy, providing an average of
19 fields (range 4 to 39) per biopsy. Results were expressed as the
percentage of interstitial area which stained for fibrosis.
The one-year biopsy specimens from our psoriasis patients were
compared to specimens obtained from kidney transplant donors
Table 1. Characteristics of study population
Characteristic Value
Number 25
Mean age [range] 43 [19—66]
Sex (M/F) 22/3
Mean baseline creatinine mg/dl [range] 1.0 [0.7—1.4]
Cyclosporin
Mean dose mg/kg/day 3.9 0.2
Median blood level ng/mI 94 8
No. of hypertensive patients
Baseline 5 (20%)
During cyclosporin therapy 11(44%)
Values following indicate standard error.
who had normal renal function at the time of donation. Each
patient was age and sex matched with two donor controls. As an
additional control, we used kidney biopsy specimens from 16
unmatched patients with severe psoriasis who had not received
cyclosporin and who were in the same age range as our patients
(graded by MJM and reported previously [6]). For patients with
paired biopsies, the results from the one-year and three-year
specimens were compared.
Renal ftinction tests
Glomerular filtration rate (GFR), as estimated by iothalamate
clearance, was measured in most subjects at baseline and after
approximately 2, 6, 12, 18, 24, 30, and 36 months of cyclosporin
treatment. The renal clearance of subcutaneously injected 125I
iothalamate (IsoTex Diagnostics, Friendswood, Texas, USA) was
measured using standard techniques [2, 7]. The serum creatinine
concentration was measured at frequent intervals during treat-
ment using an autoanalyzer method.
Statistical analysis
The paired t-test was used to compare the paired scores from
the one-year biopsy with the matched donor controls and to
compare the paired scores from the one-year and three-year
kidney biopsies [8]. The two-sample t-test was used to compare
the one-year biopsy with the unpaired psoriatic control specimens
[8]. For individual patients, the rates of change of iothalamate
clearance and reciprocal serum creatinine (l/Sr) over time were
determined by least-squares linear regression using all measure-
ments performed while the patient was taking cyclosporin. Slopes
with 95% confidence intervals were used to describe the mean
rates of change of iothalamate clearance and reciprocal serum
creatinine. Potential predictors of cyclosporin toxicity were eval-
uated by linear regression. Results are given as mean SEM unless
otherwise noted. All P values are two-tailed.
Results
Patient characteristics
Baseline characteristics of the 25 patients who entered the
long-term study of the renal effects of cyclosporin are given in
Table 1. In this subset of the original study population, the
maximum cyclosporin dose (administered for less than two
months) was 7.5 mg/kg per day in six patients, 5 mg/kg per day in
16 patients, and 4 mg/kg per day in the remainder. The average
dose throughout the study was 3.9 mg/kg per day.
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A B C
Matched
kidney
donor Untreated
Cyclosporin-
treated P value
controls1' psoriatic psoriasis(N = 19
pairs)
controls"
(N 16) patients(N 19)
C vs. C vs.
A" B"
Age 45 3 43 3 44 3 0.8 0.8
Interstitial 0.3 0.1 0.3 0.2 1.9 0.2 <0.0001 <0.0001
fibrosis score1
Tubular atrophy
score1
0.3 0.1 0.4 0.2 1.6 0.2 <0.0001 <0.0001
Arteriolar 0.5 0.1 0.6 0.2 0.6 0.2 0.4 0.8
hyalinosis
score1
Arteriolopathy
score1
ND ND 0 NA NA
Obsolescent 2.4 0.9 4.1 1.5 5.5 1.3 0.08 0,5
glomeruli %
Juxtaglomerular 0.8 0.4 ND 1.9 0.7 0.2 NA
apparatus
hypertrophy
%
"Results are mean SEM; Abbreviations are: ND, not done; NA, not
applicable.
Kidney specimens were obtained from two different kidney donors
with normal renal function who were age- and sex-matched for each
cyclosporin-treated patient.
C Kidney specimens obtained from psoriasis patients who had not been
treated with cyclosporin [6].
d By paired i-test.
"By unpaired i-test.
1Assessed by an ordinal scale [3, 4] where 0 indicates the absence of the
characteristic and 4 indicates a severe degree of the characteristic.
Renal structural changes
An interpretable initial kidney biopsy specimen was obtained
from 19 patients who had received cyclosporin for an average of
1.1 0.1 years. The scores for interstitial fibrosis and tubular
atrophy were significantly higher in specimens from the cyclo-
sporin-treated patients than from the untreated transplant donors
and the untreated psoriasis patients (Table 2, Fig. 1). Non-specific
arteriolar hyalinosis was found in control and patient specimens.
Characteristic cyclosporin-related arteriolopathy was absent in
patient specimens. The percentage of glomeruli showing obsoles-
cence and juxtaglomerular hypertrophy did not differ in patient
and control specimens.
After approximately three years of cyclosporin therapy, addi-
tional renal structural injury was evident in the biopsy specimens
(Fig. 1 summarizes the data from 19 patients who had a biopsy at
1 year and 14 patients who had a biopsy at 3 years). Eleven
patients (10 men and one woman) had two biopsies taken 2.1
0.1 years apart. There was an increase in the interstitial fibrosis,
tubular atrophy, and chronicity index scores in the three-year
biopsy compared to the one-year biopsy (Table 3,Fig. 2). Simi-
larly, an increase in the quantitative digital morphometric mea-
sure of interstitial fibrosis was observed in all patients (Table 3,
Fig. 3). Transmural deposits of the arteriolar wall were absent in
all 11 initial biopsies but were present in the second biopsy
specimens from five patients, yielding a higher arteriolopathy
score (Table 3).
Fig. 1. Cumulative frequency distribution of the sum of interstitial fibrosis
and tubular atrophy scores for donor control specimens (N = 38, broken
line), psoriatic control specimens (N = 16, solid line), and for the first (N
19, thick line) and second (N = 14, thick dashed line) kidney biopsies taken
from cyclosporin-treated psoriasis patients.
Table 3. Summary scores for the 11 patients who had two kidney
biopsies"
1-year
biopsy
3-year
biopsy P value"
Duration of cyclosporin treatment 1.1 0.1 3.4 0.1 NA
years
Interstitial fibrosis score" 1.8 0.2 2.5 0,2 0.002
Tubular atrophy score" 1.5 0.2 1.9 0.2 0.053
Arteriolar hyalinosis score" 0.7 0.2 1.3 0.3 0.14
Arteriolopathy score" 0 0.5 0.2 0.02
Obsolescent glomeruli % 5.3 1.7 8.4 3.1 0.4
Juxtaglomerular apparatus 1.3 0.6 3.0 1.4 0.3
hypertrophy %
Chronicity index" 2.8 0,2 3.9 0.4 0.014
Quantitative morphometric interstitial 22.5 1.5 32.0 2.0 0.0008
fibrosis%e
"Results are mean SEM; Abbreviation is: NA, not applicable.bBy paired t-test.
"Assessed by an ordinal scale [3, 4] where 0 indicates absence of the
characteristic and 4 indicates a severe degree of the characteristic.
"Sum of individual lupus chronicity scores for interstitial fibrosis,
tubular atrophy, glomerular sclerosis, and fibrous crescents, each rated on
a scale of 0 to 3 (0 = absent, 1 mild, 2 = moderate, 3 = severe) [5].
"Assessed by quantitative digital analysis of all interstitial areas of
trichrome stained slides.
Renal function
Serial measurements of iothalamate clearance and serum cre-
atinine for the 16 subjects who completed three years of cyclo-
sporin treatment are shown in Figure 4. Mean iothalamate
clearance declined immediately after cyclosporin was started and
it increased when the drug was stopped. For the patients who had
both measurements, iothalamate clearance returned to 94 3%
(P = 0.08) of the baseline value when cyclosporin was discontin-
ued after one year. With the resumption of cyclosporin, iothalamate
Table 2. Histology scores for first kidney biopsy specimen and control
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Fig. 2. Kidney biopsy specimens (Mason is trichrome stain, magnification
80x) taken from a 48 year-old male autopsy control (A) and a representative
41 year-old male patient after treatment with cyclosporin for approximately
one year (B) and three years (C). Staining denotes areas of interstitial
fibrosis involving the peritubular and periglomerular regions. Quantitative
digital morphometry of the entire interstitial area demonstrated I 0.6%
fibrosis in the autopsy specimen, 19.9% fibrosis in the one-year specimen,
and 28.5% fibrosis in the three-year specimen.
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Fig. 3. Quantitative digital morphometric measurements of interstitial fibro-
sis of biopsy specimens from patients who received cyclosporin fur approxi-
mately two years between biopsies. Paired readings are connected by a line.
Vertical bars indicate mean so. The difference between the two
measurements is significant (P = 0.0008).
clearance again declined (Fig. 4). The changes in serum creatinine
generally mirrored the changes in iothalamate clearance (Fig. 4).
Trends in renal function were further analyzed by regression
analyses of iothalamate clearance versus time and reciprocal of
serum ereatinine versus time for each patient in order to estimate
the average rate of change (slope) of filtration rate. The slope
analysis was based on measurements performed while patients
were taking cyclosporin; measurements done at baseline and
during the drug withdrawal period were excluded. On average,
each patient had seven measurements of iothalamate clearance
and 46 measurements of serum creatinine. While patients were
taking cyclosporin, iothalamate clearance changed by —3.1 1.3
ml/min/1.73 m2 per year (95% CI —5.8, —0.3). For individual
patients, the iothalamate clearance declined over time in nine
(significantly different from 0 slope in 3) and increased over time
in seven (none significant). Without adjustment for body surface
area, iothalamate clearance changed by —3.0 1.5 mI/mm per
year (95% CI —6.3, 0.2). The reciprocal of serum creatinine
changed by —0.06 0.01 dl/mg per year (95% CI —0.08, —0.04).
The slope declined in all 16 patients and was significantly different
from zero in 13. During the course of therapy, the highest serum
creatinine measurement exceeded the baseline value by an aver-
age of 56 7%; most patients (75%) had at least one ereatinine
measurement during treatment that was more than 30% above the
baseline measurement. Six patients from the total group devel-
oped new hypertension while taking cyclosporin (Table 1).
Structure-function relationships and prediction of nephrotoxicity
In general, measures of renal structure were not strongly or
consistently correlated with measures of function. Interstitial
125
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Fig. 4. Serial measurements (mean sEat) of iothalamate clearance (A)
and serum creatinine (B) for 16 patients who received cyclosporin for three
years. Time 0 denotes baseline measurement before cyclosporin was
started. Value marked by "off" indicates measurement taken during a 1 to
2 month cyclosporine hiatus, approximately 12 months after initiation of
therapy. Not all patients had an iothalamate clearance measurement at
each time point; each time point represents the nearest temporal measure
from the start of the study.
fibrosis was not significantly correlated with iothalamate clearance
at baseline or at the times of biopsy. The chronicity index was
correlated with patient age (r = 0.74, P C 0.001 using the lower
ehronicity index for patients with 2 biopsies). Also, the percentage
recovery of iothalamate clearance when eyelosporin was stopped
at one year was inversely correlated with patient age (r =
—0.54,
P C 0.0001). However, the quantitative morphometric measure of
interstitial fibrosis was not related to patient age. The increase in
interstitial fibrosis from year 1 to year 3 did not differ when
patients were grouped according to whether the peak serum
ereatinine concentration exceeded the baseline value by less than
30% (43 33%, N = 2) or by greater than 30% (47 12%, N =
9). Patients who were hypertensive during eyclosporin treatment
had less complete recovery of iothalamate clearance when cyelo-
sporin was discontinued at one year (86 11% of baseline
clearance) than did normotensive patients (101 12%, P =
0.023). Hypertensive patients also had a greater increase in
interstitial fibrosis between the one-year and the three-year
kidney biopsies than did normotensive patients (76 12 vs. 22
8%, P = 0.003). Markers of nephrotoxicity were not correlated
with eyclosporin dose or blood levels (as measured by high
pressure liquid chromatography [9]).
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Discussion
Nephrotoxicity is a clinically important problem when cyclospo-
nfl is used for transplant immunosuppression; however, the risk
and expression of cyclosporin toxicity in the setting of renal
transplantation are modified by multiple other conditions includ-
ing allograft ischemia, rejection, denervation, other nephrotoxic
medications, recurrent disease, and concomitant illnesses. Cyclo-
sporin-related nephrotoxicity in non-renal transplant patients
[10—14] may also be confounded by other factors that could
contribute to renal injury such as other drugs and concomitant
illnesses. Psoriasis patients provide an excellent opportunity to
learn the direct renal effects of low-dose cyclosporin because these
individuals are free of intrinsic renal disease [6, 15] as well as most
other factors that confound the expression of cyclosporin toxicity
in transplant patients.
This study addressed changes in both renal structure and
function in otherwise normal psoriasis patients treated for up to
three years with relatively low doses of cyclosporin (that is, 5
mg/kg per day for most of the treatment period). Interstitial
fibrosis and tubular atrophy were present in all biopsies per-
formed after approximately one year of exposure to cyclosporin
whereas these features were uncommon in control specimens
from kidney donors and psoriasis patients not taking cyclosporin
(Table 2, Fig. 1). After an additional two years of cyclosporin
treatment, specimens from all patients with paired biopsies dem-
onstrated progression of interstitial, tubular, or vascular pathology
characteristic of cyclosporin nephrotoxicity [3, 4] (Table 3, Fig. 1
through 3). The processes of patient selection and drop-out from
the study tended to exclude subjects who developed overt renal
problems related to cyclosporin. Therefore, the histologic pro-
gression we found may be regarded as a conservative estimate for
the general population of cyclosporin-treated psoriasis patients.
GFR, estimated as iothalamate clearance, showed a slow but
significant decline while patients were taking cyclosporin (Fig. 4).
The rapid return of GFR toward the baseline value when cyclo-
sporin was temporarily discontinued indicates a reversible com-
ponent of renal dysfunction, presumably due to cyclosporin-
induced vasoconstriction. However, the overall downward trend
in filtration function persisted throughout the period of cyclospo-
nfl treatment. In our selected sample of patients, iothalamate
clearance declined at an overall rate of —3.0 mI/mm per year
(95% CI —6.2, 0.2), whereas the reported age-related fall in
creatinine clearance is —0.75 0.12 ml/min per year (mean SE)
for normal individuals and —0.92 0.32 mi/mm per year for
subjects with treated hypertension [16]. In our patients the slope
of reciprocal serum creatinine fell by —0,06 dl/mg per year (95%
CI —0.08, —0.04) as compared to a reported rate of —0.009
0.001 dl/mg per year (mean SE) for white men with mild to
moderate, treated hypertension [17]. While our patients appeared
to lose GFR faster than expected, it is uncertain if the rapid
decline is attributable to structural injury or reversible vasocon-
striction. Follow-up studies of cyclosporin are planned to assess
the long-term functional significance of the renal injury.
In agreement with our findings, Zachariae et al reported an
increase in interstitial connective tissue and fibrosis in each of 12
psoriasis patients treated with low-dose cyclosporin for six to 18
months [15]. Powles et al found tubular atrophy and vascular
changes in biopsy specimens from a selected group of six psoriasis
patients treated with cyclosporin for five years; interstitial fibrosis
was found in specimens from four of the patients [18]. The
International Kidney Biopsy Registry of Cyclosporin in Autoim-
mune Diseases reported a 29% incidence of biopsy-proven neph-
rotoxicity among adults; however, renal injury was absent in all 11
psoriasis patients included in the registry [19}. The same pathol-
ogist (MJM) contributed to both the registry study [19] and the
current study. In the registry study, nephrotoxicity was unusual if
the serum creatinine concentration during treatment increased by
less than 30%. It may be noteworthy that most of our patients had
at least one creatinine measurement that was 30% above the
baseline value. However, in our small sample we did not find that
the increment in serum creatinine predicted progressive fibrosis.
Our results are in agreement with others who have found that
cyclosporin treatment is associated with a fall in estimated GFR in
non-transplant patients [2, 13, 15, 18, 20—23]. The long-term effect
of cyclosporin on GFR in non-transplant patients is unknown
except for the suggestion from our study that the age-related fall
in GFR is more rapid than expected while patients are taking the
drug.
The poor correlation between renal structural and functional
measurements could be due to the relatively small sample size or
to a variable mixture of vasoconstrictive and fibrotic components
to the functional changes. Marked dissociation between GFR and
histology was also found in an experimental model of cyclosporin
nephrotoxicity [24]. The presence of hypertension during cyclo-
sporin therapy predicted a greater degree of progressive renal
interstitial fibrosis on serial biopsies. Our data suggest that older
patients may be more vulnerable to cyclosporin-induced renal
injury. No clinical measurement predicted the magnitude of renal
histologic changes in individual patients.
Although published reports differ regarding the frequency and
extent of nephrotoxicity, our longitudinal study clearly shows that
cyclosporin is associated with renal structural changes and a small
decline in GFR. The clinical predictors of cyclosporin nephrotox-
icity are imprecise when applied prospectively to individual pa-
tients. While the long-term renal consequences of cyclosporin
treatment in non-transplant patients are uncertain, it is known
that interstitial fibrosis is associated with diminished renal func-
tion [25]. At this time it would be reasonable to exercise caution
in the long-term use of cyclosporin for patients with psoriasis.
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